On December 12 at 10:00 CET, InDex CEO Peter Zerhouni will give an overview of how the company sees the way forward towards phase III based on the successful phase IIb study CONDUCT with the drug candidate cobitolimod. The presentation concludes with a Q&A session together with InDex Pharmaceuticals...
Read more
12 December 2019
20 February 2020